• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Annexin Pharmaceuticals

12.50 SEK

0.00 %

Less than 1K followers

ANNX

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
0.00 %
-6.01 %
-5.31 %
-36.24 %
-35.91 %
-54.84 %
-75.23 %
-86.77 %
-96.03 %

Annexin Pharmaceuticals is a biotechnology company developing the drug candidate ANXV, based on the protein Annexin A5, for the treatment of diseases such as vascular damage, inflammation and certain cancers. The company's partners are healthcare providers and biopharmaceutical companies and the business is aimed at global markets through research and licensing collaborations. The company was founded in 2014 and is headquartered in Stockholm, Sweden.

Read more
Market cap
109.42M SEK
Turnover
144.65K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Press releases
ShowingAll content types

Financial calendar
16/7
2026

Interim report Q2'26

22/10
2026

Interim report Q3'26

11/2
2027

Annual report '26

Regulatory press release2026-07-03 13:15

Annexins företrädesemission 98 procent tecknad

Annexin Pharmaceuticals
Regulatory press release2026-07-03 13:15

Annexin's rights issue 98 percent subscribed

Annexin Pharmaceuticals
Press release2026-06-23 10:00

Investor Studios: Annexin Pharmaceuticals om NEXUS-studien och företrädesemission

Annexin Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2026-06-23 08:30

Annexin uppdaterar om fortsatt lovande data från NEXUS studien – som visar på förbättrad blodförsörjning i näthinnan i både DR och RVO

Annexin Pharmaceuticals
Press release2026-06-23 08:30

Annexin updates on continuous promising data from the NEXUS study – demonstrating improvement of retinal perfusion in both DR and RVO

Annexin Pharmaceuticals
Regulatory press release2026-06-15 08:30

Idag börjar teckningsperioden i Annexin Pharmaceuticals företrädesemission

Annexin Pharmaceuticals
Regulatory press release2026-06-15 08:30

The subscription period in Annexin Pharmaceuticals’ rights issue begins today

Annexin Pharmaceuticals
Regulatory press release2026-06-10 08:30

Annexin Pharmaceuticals offentliggör Informationsdokument med anledning av förestående företrädesemission

Annexin Pharmaceuticals
Regulatory press release2026-06-10 08:30

Annexin Pharmaceuticals publishes Information document in connection with forthcoming rights issue

Annexin Pharmaceuticals
Press release2026-06-05 08:30

Annexin Pharmaceuticals presenterar på Aktiedagarna i Stockholm den 10 juni

Annexin Pharmaceuticals
Press release2026-06-05 08:30

Annexin Pharmaceuticals to present at Aktiedagarna in Stockholm on June 10

Annexin Pharmaceuticals
Regulatory press release2026-06-03 22:50

Annexin genomför företrädesemission om cirka 20 MSEK, säkerställd till cirka 60 procent, med en övertilldelningsoption om upp till cirka 5 MSEK

Annexin Pharmaceuticals
Regulatory press release2026-06-03 22:50

Annexin resolves a rights issue of approximately SEK 20 million, secured to approximately 60 percent, with an overallotment option of up to approximately SEK 5 million

Annexin Pharmaceuticals
Press release2026-05-21 08:30

Annexin utvärderar en tredagarsbehandling med ANXV för patienter med RVO

Annexin Pharmaceuticals
Press release2026-05-21 08:30

Annexin investigates a three-day ANXV treatment regimen in patients with RVO

Annexin Pharmaceuticals
Regulatory press release2026-05-12 16:00

Kommuniké från årsstämma i Annexin Pharmaceuticals AB

Annexin Pharmaceuticals
Press release2026-05-11 08:30

Annexin får kliniskt prövningsgodkännande i Tyskland – breddar patientrekryteringen i NEXUS-studien

Annexin Pharmaceuticals
Press release2026-05-11 08:30

Annexin receives clinical trial approval in Germany, widening patient recruitment in the NEXUS study

Annexin Pharmaceuticals
Press release2026-04-24 09:40

Redeye: Annexin Pharmaceuticals (Q1 review): Study on track

Annexin Pharmaceuticals
Regulatory press release2026-04-23 08:30

Annexin Pharmaceuticals delårsrapport januari - mars 2026

Annexin Pharmaceuticals